GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arrowhead Pharmaceuticals Inc (STU:HDP1) » Definitions » EBIT

Arrowhead Pharmaceuticals (STU:HDP1) EBIT : €-420.28 Mil (TTM As of Mar. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Arrowhead Pharmaceuticals EBIT?

Arrowhead Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was €-110.17 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was €-420.28 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Arrowhead Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2024 was -124.58%. Arrowhead Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -122.67%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Arrowhead Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -16.78%.


Arrowhead Pharmaceuticals EBIT Historical Data

The historical data trend for Arrowhead Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arrowhead Pharmaceuticals EBIT Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 55.56 -79.09 -119.72 -174.44 -176.31

Arrowhead Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.25 -90.66 -97.19 -122.26 -110.17

Competitive Comparison of Arrowhead Pharmaceuticals's EBIT

For the Biotechnology subindustry, Arrowhead Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arrowhead Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Arrowhead Pharmaceuticals's EV-to-EBIT falls into.



Arrowhead Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-420.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arrowhead Pharmaceuticals  (STU:HDP1) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Arrowhead Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-464.384 * ( 1 - 0% )/( (359.711 + 385.809)/ 2 )
=-464.384/372.76
=-124.58 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=574.304 - 54.874 - ( 201.996 - max(0, 58.434 - 218.153+201.996))
=359.711

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=878.738 - 54.572 - ( 481.265 - max(0, 59.961 - 498.318+481.265))
=385.809

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Arrowhead Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-440.688/( ( (346.918 + max(-39.14, 0)) + (371.568 + max(-38.046, 0)) )/ 2 )
=-440.688/( ( 346.918 + 371.568 )/ 2 )
=-440.688/359.243
=-122.67 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 16.157) - (54.874 + 0 + 0.42299999999999)
=-39.14

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 17.053) - (54.572 + 0 + 0.52699999999999)
=-38.046

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Arrowhead Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=-420.283/2504.188
=-16.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arrowhead Pharmaceuticals EBIT Related Terms

Thank you for viewing the detailed overview of Arrowhead Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Arrowhead Pharmaceuticals (STU:HDP1) Business Description

Traded in Other Exchanges
Address
177 E. Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Arrowhead Pharmaceuticals (STU:HDP1) Headlines

No Headlines